华夏创新医药龙头基金

Search documents
公募看好下半年市场 青睐创新药、AI与新消费
Shen Zhen Shang Bao· 2025-06-29 17:23
Group 1 - The core viewpoint is that Chinese equity assets are showing long-term allocation value amid global asset rebalancing, with a focus on sectors like innovative pharmaceuticals, AI, and new consumption [1][2] - Jiashi Fund expresses optimism for the next 6-12 months, citing China's stable growth policies and the ongoing development of new industries as key drivers for global economic growth [1] - Jiashi Fund recommends a "barbell" strategy for equity assets, focusing on high-growth technology assets supported by liquidity and high-dividend, cyclical assets [1] Group 2 - Hu Yu, manager at Tianhong Fund, emphasizes the importance of the rotation between consumption and technology as a core strategy for the second half of the year, highlighting the early stage of consumption recovery [2] - Fuguo Fund notes that the AI sector is expected to be a central theme for technology investment in the second half, driven by significant cost reductions and a surge in domestic AI investments [2] - The report indicates that the upstream of the AI industry chain is experiencing a convergence of advantages compared to the mid and downstream sectors, suggesting potential for broader market growth [2]